INOVIO has announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.

Dr. Shea will provide a brief overview of INOVIO and then participate in a panel discussion entitled ‘Innovative Technologies for Treating and Preventing Disease,’ which will be moderated by Roy Buchanan, biotechnology analyst at Citizens JMP.

The Citizens JMP Novel Therapeutics Forum will take place at the Jordan Medical Education Center at the Perelman Center for Advanced Medicine but will not be webcast.

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its disease-fighting tools.

In January 2024, INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with locoregionally advanced, high-risk, HPV-16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer.

Under the terms of the agreement, Coherus will provide LOQTORZI for a planned clinical trial at no cost to INOVIO.

LOQTORZI is a PD-1 inhibitor recently approved by the FDA for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma.

INO-3112 is a DNA medicine candidate targeting HPV-16/18 combined with a DNA plasmid for IL-12 as an immune activator. INOVIO has submitted the proposed design of a Phase 3 trial to the FDA with the intent to evaluate the clinical benefit of INO-3112 in combination with a PD-1 inhibitor.

Feedback on the clinical development plan is expected in the second quarter of 2024. If cleared to proceed by the FDA, the trial will investigate if LOQTORZI can help boost the tumor-infiltrating abilities of the antigen-specific T cells generated by INO-3112.